MegaPro Biomedical Co., Ltd. (6827)
Market Closed
11 Aug, 05:30
TWSE TWSE Primary NT$
10. 15
-0.1
-0.9756%
NT$
1B Market Cap
- P/E Ratio
- Div Yield
25,026 Volume
- Eps
NT$ 10.25
Previous Close Want to track 6827 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
6827 closed today lower at NT$10.15, a decrease of -0.9756% from yesterday's close, completing a monthly decrease of -17.1429% or -NT$2.1. Over the past 12 months, 6827 stock lost -20.3922%.
6827 is not paying dividends to its shareholders.
MegaPro Biomedical Co., Ltd. has completed 1 stock splits, with the recent split occurring on Jun 30, 2014.
The company's stock is traded on one exchange.
6827 Chart
MegaPro Biomedical Co., Ltd. (6827) FAQ
What is the stock price today?
The current price is NT$10.15.
On which exchange is it traded?
MegaPro Biomedical Co., Ltd. is listed on TWSE.
What is its stock symbol?
The ticker symbol is 6827.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 1B.
Has MegaPro Biomedical Co., Ltd. ever had a stock split?
MegaPro Biomedical Co., Ltd. had 1 splits and the recent split was on Jun 30, 2014.
MegaPro Biomedical Co., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | - CEO | TWSE Exchange | TW0006827009 ISIN |
| Taiwan Country | - Employees | - Last Dividend | 30 Jun 2014 Last Split | - IPO Date |
Overview
MegaPro Biomedical Co., Ltd is a pioneering biotech company with a core focus on the development of nano drugs aimed at improving medical treatments and outcomes. Founded in 2014 and headquartered in Zhubei, Taiwan, the company stands at the forefront of innovative therapies, particularly in the fields of oncology and iron deficiency anemia. Its mission is to advance healthcare solutions through nanotechnology, targeting complex diseases with precision and efficiency.
Products and Services
MegaPro Biomedical Co., Ltd has been instrumental in the development of several key pharmaceutical products, each at various stages of clinical trials. These include:
- MPB-1523: Currently in Phase II clinical trial, MPB-1523 is an Intraocular Pressure (IOP) injection designed for the treatment of hepatocellular carcinoma. The drug represents a significant advancement in the fight against liver cancer, offering a targeted therapeutic approach.
- MPB-1514: This iron injection is also in Phase II clinical trial, aimed at treating iron deficiency anemia. MPB-1514 showcases the company's commitment to addressing common yet critical health issues through innovative nanomedicine techniques.
- MPB-1734: An anti-cancer drug that is currently in the preclinical trial stage. MPB-1734 is being developed for the treatment of malignant tumors, highlighting MegaPro Biomedical's dedication to expanding its oncology portfolio with cutting-edge nanotechnology solutions.
Contact Information
Address: No. 66, Shengyi 5th Rd.
Phone: 886 3 591 0360
Website: https://www.megaprobio.com
